乳房植入物相关间变性大细胞淋巴瘤的遗传学特征
本文综述了乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)的遗传学改变。BIA-ALCL 为 CD30 阳性 T 细胞非霍奇金淋巴瘤,与乳房植入物相关。下一代测序显示其 ALK、DUSP22、TP63 重排阴性,但 JAK-STAT3 通路持续激活,部分病例存在 JAK1 和/或 STAT3 复发性体细胞突变(分别为 13% 和 26%),另有 DNMT3A 和 TP53 点突变。
要点
- BIA-ALCL 持续缺乏 ALK、DUSP22 和 TP63 基因重排。
- JAK-STAT3 通路在 BIA-ALCL 中组成性激活,JAK1 突变占 13%(3/23),STAT3 突变占 26%(6/23)。
- 靶向抑制 JAK-STAT 信号的治疗可能为晚期 BIA-ALCL 提供新选择。
核心结论
- BIA-ALCL 具有比系统性及原发性皮肤 ALCL 更一致的分子特征。
- JAK-STAT3 通路激活及 JAK1/STAT3 突变是 BIA-ALCL 的潜在治疗靶点。
研究设计与样本
- 综述类:基于下一代测序研究汇总 BIA-ALCL 的遗传学改变。
主要发现
- BIA-ALCL 为 CD30 阳性 T 细胞非霍奇金淋巴瘤,与乳房植入物相关。
- BIA-ALCL 持续阴性 for ALK、DUSP22 和 TP63 基因重排。
- JAK1 和/或 STAT3 激活突变分别见于 13%(3/23)和 26%(6/23)的 BIA-ALCL。
- 其他遗传改变包括 DNMT3A 和 TP53 点突变。
关键数值与推荐
- JAK1 突变频率 13%(3/23);STAT3 突变频率 26%(6/23)。
- BIA-ALCL 中 ALK、DUSP22、TP63 重排均为阴性。
临床怎么用
- 对 BIA-ALCL 患者可考虑检测 JAK1/STAT3 突变。
- JAK-STAT 信号抑制剂可能用于晚期 BIA-ALCL 的靶向治疗。
局限性
- 已检测病例数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. However, the JAK-STAT3 pathway is constitutively activated in BIA-ALCL, which in some cases is associated with recurrent somatic mutations of JAK1 and/or STAT3. These activating mutations, which may be concurrent, are identified in 13% (3/23) and 26% (6/23) of BIA-ALCLs, respectively. Other genetic alterations include point mutations of DNMT3A and TP53. Although the number of examined cases has been limited, these findings suggest that BIA-ALCL shows more uniform molecular features than systemic and primary cutaneous ALCLs, which show considerable genetic heterogeneity. Targeted therapies inhibiting JAK-STAT signaling are being developed and may offer novel therapeutic options for patients with BIA-ALCL, especially those with advanced disease.
引用
- Oishi N, Miranda RN, Feldman AL, et al. Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019. PMID: 30715169. doi:10.1093/asj/sjy311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。